Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Kathleen Jentsch-Ullrich"'
Autor:
Florian Simon, Rudy Ligtvoet, Thomas Noesslinger, Jan-Paul Bohn, Julia Von Tresckow, Rüdiger Liersch, Tobias Gaska, Kathleen Jentsch-Ullrich, Michael Koenigsmann, Thomas Wolff, Ingo Schwaner, Dominik Wolf, Christof Schneider, Eugen Tausch, Stephan Stilgenbauer, Karl-Anton Kreuzer, Sandra Robrecht, Anna-Maria Fink, Moritz Fürstenau, Kirsten Fischer, Valentin Goede, Michael Hallek, Barbara Eichhorst
Publikováno v:
HemaSphere, Vol 7, p e3844763 (2023)
Externí odkaz:
https://doaj.org/article/8a43f0f54e4c40a8b2e60240c8a0ce55
Autor:
Georg-Nikolaus Franke, Gunnar Loewe, Marcel Reiser, Hartmut Linde, Andreas Josting, Eyck von der Heyde, Rudolf Weide, Hans Tesch, Arndt Nusch, Jolanta Dengler, Kathleen Jentsch-Ullrich
Publikováno v:
HemaSphere, Vol 7, p e4962270 (2023)
Externí odkaz:
https://doaj.org/article/e75f25079aee4426a4e5fc7952668e0c
Autor:
Ulrich Dührsen, Stefanie Broszeit‐Luft, Annette Dieing, Andreas Lück, Piotr Porowski, Marcel Reiser, Ulrike Schwinger, Sandra Klawitter, Katja Krumm, Kathleen Jentsch‐Ullrich
Publikováno v:
Cancer Medicine, Vol 7, Iss 7, Pp 2903-2912 (2018)
Abstract Standard of care for patients with symptomatic, advanced‐stage follicular lymphoma (FL) is rituximab‐containing chemoimmunotherapy followed by rituximab maintenance. This prospective, multicenter, noninterventional study analyzed how eff
Externí odkaz:
https://doaj.org/article/8d0721bd9e7f4b1aaea286c0d1dfc014
Publikováno v:
Annals of Hematology. 102:1617-1620
Autor:
Andreas Schmidt, Christiane Bernhardt, Dieter Bürkle, Stefan Fries, Carla V. Hannig, Kathleen Jentsch-Ullrich, Andreas Josting, Stephan Kreher, Marcel Reiser, Hans Tilman Steinmetz, Hans Tesch, Stephanie Terner, Alexander Schulte, Carl C. Crodel, Francesca Palandri, Florian H. Heidel
Publikováno v:
Journal of Cancer Research and Clinical Oncology.
Purpose The WHO 2016 re-classification of myeloproliferative neoplasms resulted in a separation of essential thrombocythemia (ET) from the pre-fibrotic and fibrotic (overt) phases of primary myelofibrosis (MF). This study reports on a chart review co
Autor:
Jesko Momotow, Ina Bühnen, Karolin Trautmann‐Grill, Guido Kobbe, Dennis Hahn, Roland Schroers, Bernhard Heinrich, Tobias Gaska, Helmut Forstbauer, Burkhard Schmidt, Regina Boger, Andreas Hüttmann, Gerhard Heil, Doris M. Kraemer, William Krüger, Vanja Zeremski, Norbert Grobe, Kathleen Jentsch‐Ullrich, Frank Griesinger, Michael Fuchs, Bastian von Tresckow, Peter Borchmann, Andreas Engert, Paul J. Bröckelmann
Publikováno v:
British Journal of Haematology. 198:401-404
Autor:
Jolanta Dengler, Hans Tesch, Kathleen Jentsch-Ullrich, Anke Gerhardt, Clemens Schulte, Jörg Lipke, Gunnar Löwe, Alexander Kiani
Publikováno v:
Acta Haematologica. 145:603-610
Introduction: Treatment-free remission (TFR) is increasingly considered as treatment goal for patients with chronic myeloid leukemia (CML), but information on the disposition and outcome of TFR in clinical practice is scarce. Here, we report the char
Autor:
Rainer Krahl, Thoralf Lange, Dietger Niederwieser, Christian Niederwieser, Ulrich von Grünhagen, Volker Lakner, Markus Pfirrmann, Kathleen Jentsch-Ullrich, Claudia Spohn, Michael Cross, Haifa Kathrin Al-Ali, Arthur Gil, Rüdiger Hehlmann, Christian Junghanss, Michael Assmann, Michael W. Deininger
Publikováno v:
Leukemia & Lymphoma. 61:2821-2830
The combination of Imatinib (IM) and hydroxyurea (HU) was explored for the treatment of chronic myelogenous leukemia (CML).AfterAdditive specific inhibition of CML cells by IM/HU was detectedIM/HU combination was more potent in selectively inhibiting
Autor:
Marie von Lilienfeld-Toal, Francesca Palandri, Andreas Hochhaus, Guiseppe Auteri, Verena Hofmann, Carl C Crodel, Denise Wolleschak, Philipp Ernst, Frank Stegelmann, Martin Griesshammer, Tobias Rachow, Steffen Koschmieder, Stefanie Jilg, Susanne Isfort, Annamaria Brioli, Florian H. Heidel, Dietrich Kämpfe, Konstanze Döhner, Kathleen Jentsch-Ullrich, Philipp J. Jost
Publikováno v:
Leukemia
Autor:
Vanja Zeremski, Kathleen Jentsch-Ullrich, Judith Eberhardt, Enrico Schalk, Thomas Fischer, Christoph Kahl, Martin Mohren
Publikováno v:
Annals of Hematology. 98:2729-2737
Despite bendamustine-rituximab (BR) showed disappointing efficacy in diffuse large B cell lymphoma (DLBCL), it is still occasionally used as first-line treatment in older DLBCL patients instead of recommended R-CHOP. This multicentre, retrospective s